207_Combined course Presentations
Toxicity of concurrent SRT and immune checkpoint inhibition
Anti-PD-1/PD-L1 (nivolumab, pembrolizumab)
Data on combined SRT and nivolumab is insufficient for conclusions, both for cranial and extra-cranial SRT.
Data about the combination of pembrolizumab with SRT is not available.
Kroeze S et al. Cancer Treatment Reviews 53 (2017) 25–37
Made with FlippingBook